Redeye reiterates its positive view on Isofol shares following the license deal for the Canadian market for arfolitixorin. The first local deal in a Western market with a major specialty pharma company represents an important milestone for Isofol, in our view. We believe the deal terms support our valuation assumptions for arfolitixorin.